Elevated PD-L1 levels after EGFR TKI resistance can indicate worse prognosis.Targeting PD-L1 or related pathways (STAT3, ERK1/2) may enhance response in EGFR TKI–resistant NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.